1. Home
  2. MLYS vs PCRX Comparison

MLYS vs PCRX Comparison

Compare MLYS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • PCRX
  • Stock Information
  • Founded
  • MLYS 2019
  • PCRX 2006
  • Country
  • MLYS United States
  • PCRX United States
  • Employees
  • MLYS N/A
  • PCRX N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MLYS Health Care
  • PCRX Health Care
  • Exchange
  • MLYS Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • MLYS 526.1M
  • PCRX 1.2B
  • IPO Year
  • MLYS 2023
  • PCRX 2011
  • Fundamental
  • Price
  • MLYS $10.86
  • PCRX $26.09
  • Analyst Decision
  • MLYS Strong Buy
  • PCRX Buy
  • Analyst Count
  • MLYS 2
  • PCRX 10
  • Target Price
  • MLYS $30.00
  • PCRX $29.30
  • AVG Volume (30 Days)
  • MLYS 263.5K
  • PCRX 892.8K
  • Earning Date
  • MLYS 03-20-2025
  • PCRX 02-27-2025
  • Dividend Yield
  • MLYS N/A
  • PCRX N/A
  • EPS Growth
  • MLYS N/A
  • PCRX N/A
  • EPS
  • MLYS N/A
  • PCRX N/A
  • Revenue
  • MLYS N/A
  • PCRX $694,957,000.00
  • Revenue This Year
  • MLYS N/A
  • PCRX $5.14
  • Revenue Next Year
  • MLYS N/A
  • PCRX $2.44
  • P/E Ratio
  • MLYS N/A
  • PCRX N/A
  • Revenue Growth
  • MLYS N/A
  • PCRX 4.40
  • 52 Week Low
  • MLYS $8.58
  • PCRX $11.16
  • 52 Week High
  • MLYS $16.91
  • PCRX $31.67
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 51.57
  • PCRX 77.75
  • Support Level
  • MLYS $9.81
  • PCRX $25.06
  • Resistance Level
  • MLYS $10.79
  • PCRX $27.10
  • Average True Range (ATR)
  • MLYS 0.62
  • PCRX 1.45
  • MACD
  • MLYS 0.15
  • PCRX 0.28
  • Stochastic Oscillator
  • MLYS 100.00
  • PCRX 86.23

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Share on Social Networks: